Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.

S. Blagden; I. Rizzuto; C. Stavraka; D. O'Shea; P. Suppiah; M. Patel; A. Sukumaran; Naomi Loyse; N. Bharwani; A. Rockall; H. Gabra; M. El-Bahrawy; H. Wasan; R. Leonard; Nagy A. Habib; J. Gribben; Essam A Ghazaly; C. McGuigan

DOI:10.1200/JCO.2015.33.15_SUPPL.2514

Corpus ID: 78670845

Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.

@article{Blagden2015FinalRO,
  title={Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.},
  author={S. Blagden and I. Rizzuto and C. Stavraka and D. O'Shea and P. Suppiah and M. Patel and A. Sukumaran and Naomi Loyse and N. Bharwani and A. Rockall and H. Gabra and M. El-Bahrawy and H. Wasan and R. Leonard and Nagy A. Habib and J. Gribben and Essam A Ghazaly and C. McGuigan},
  journal={Journal of Clinical Oncology},
  year={2015},
  volume={33},
  pages={2514-2514}
}

S. Blagden, I. Rizzuto, +15 authors C. McGuigan

Published 2015

Medicine

Journal of Clinical Oncology

2514 Background: NUC-1031 is a first-in-class nucleotide analogue utilising phosphoramidate chemistry to enhance anti-cancer efficacy and safety. In preclinical studies NUC-1031 demonstrated potent anti-cancer activity, generating high intracellular levels of the active cytotoxic di-fluoro-deoxycytidine triphosphate (dFdCTP) by overcoming key drug resistance mechanisms associated with nucleoside analogues. Methods: This study was comprised of 1) dose escalation part: 3–8 patients (pts) per… CONTINUE READING

View via Publisher